De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

MannKind Toekomstige groei

Future criteriumcontroles 4/6

De verwachting is dat MannKind de winst en omzet met respectievelijk 39.4% en 14% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 38.6% per jaar.

Belangrijke informatie

39.2%

Groei van de winst

38.5%

Groei van de winst per aandeel

Biotechs winstgroei	28.3%
Inkomstengroei	14.0%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	04 Oct 2024

Recente toekomstige groei-updates

Recent updates

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Oct 03

MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Sep 18

Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

Jul 17

MannKind Outperforms As Tyvaso DPI Captures Market Share

May 15

This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

Mar 03

MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Mar 02

MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

Jan 27

Mannkind Corporation: Ready For Your Biotech Portfolio

Sep 01

New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Aug 19

MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed

Aug 09

MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?

Feb 25

MannKind: A Promising Player In The Inhalable Insulin Market

Feb 08

US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Aug 14

Lytham Partners Summer 2021 Investor Conference

Jun 14

MannKind (MNKD) Investor Presentation - Slideshow

Jun 04

MannKind reduces debt by $49.5M and restructures remaining obligations

Apr 26

Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

Feb 22

MannKind to co-promote Thyquidity

Dec 17

Winst- en omzetgroeiprognoses

NasdaqGM:MNKD - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	395	116	N/A	46	4
12/31/2025	337	71	N/A	45	4
12/31/2024	290	28	N/A	42	3
6/30/2024	248	12	18	41	N/A
3/31/2024	225	8	3	40	N/A
12/31/2023	199	-12	-8	34	N/A
9/30/2023	177	-31	-32	10	N/A
6/30/2023	158	-47	-57	-27	N/A
3/31/2023	128	-71	-72	-61	N/A
12/31/2022	100	-87	-88	-81	N/A
9/30/2022	76	-98	-98	-91	N/A
6/30/2022	66	-88	-89	-78	N/A
3/31/2022	70	-94	-83	-67	N/A
12/31/2021	75	-81	-73	-62	N/A
9/30/2021	81	-79	-60	-49	N/A
6/30/2021	75	-86	-54	-47	N/A
3/31/2021	66	-61	-35	-30	N/A
12/31/2020	65	-57	-33	-28	N/A
9/30/2020	63	-45	-34	-33	N/A
6/30/2020	62	-44	-73	-72	N/A
3/31/2020	62	-46	-91	-88	N/A
12/31/2019	63	-52	-91	-88	N/A
9/30/2019	63	-47	-61	-58	N/A
6/30/2019	53	-61	-22	-20	N/A
3/31/2019	42	-71	-28	-28	N/A
12/31/2018	28	-87	-38	-38	N/A
9/30/2018	16	-110	-93	-93	N/A
6/30/2018	13	-119	-102	-102	N/A
3/31/2018	12	-131	N/A	-95	N/A
12/31/2017	11	-117	N/A	-65	N/A
9/30/2017	20	-31	N/A	-48	N/A
6/30/2017	180	129	N/A	-47	N/A
3/31/2017	178	134	N/A	-39	N/A
12/31/2016	175	126	N/A	-78	N/A
9/30/2016	162	-205	N/A	-88	N/A
6/30/2016	N/A	-364	N/A	-85	N/A
3/31/2016	N/A	-363	N/A	-91	N/A
12/31/2015	N/A	-368	N/A	-57	N/A
9/30/2015	N/A	-128	N/A	-70	N/A
6/30/2015	N/A	-133	N/A	50	N/A
3/31/2015	N/A	-177	N/A	44	N/A
12/31/2014	N/A	-198	N/A	4	N/A
9/30/2014	N/A	-216	N/A	6	N/A
6/30/2014	N/A	-230	N/A	-127	N/A
3/31/2014	N/A	-203	N/A	-134	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei MNKD ( 39.4% per jaar) ligt boven de spaarquote ( 2.5% ).

Winst versus markt: De winst van MNKD ( 39.4% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.2% per jaar).

Hoge groeiwinsten: De winst van MNKD zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van MNKD ( 14% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van MNKD ( 14% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van MNKD naar verwachting over 3 jaar hoog zal zijn

MannKind Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 9.8% to US$7.25

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 8.1% to US$6.67

Consensus forecasts updated

Price target decreased to US$5.50

Consensus estimates of losses per share improve by 15%

Recent updates

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Mannkind Corporation Announces Top-Level 30-Week Results from Its Phase 4 Inhale-3 Study

MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

MannKind Corporation Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Mannkind Corporation Announces Board Changes, September 30, 2024

MannKind Corporation to Report Q2, 2024 Results on Aug 07, 2024

Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

MannKind Corporation Announces Positive 17-Week Results from the INHALE-3 Study

MannKind Outperforms As Tyvaso DPI Captures Market Share

New major risk - Financial position

MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

MannKind Corporation to Report Q1, 2024 Results on May 08, 2024

MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases

MannKind Corporation, Annual General Meeting, May 15, 2024

MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024

MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024

MannKind Corporation Announces INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Full year 2023 earnings: EPS and revenues exceed analyst expectations

MannKind Corporation to Report Q4, 2023 Results on Feb 27, 2024

MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®

MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation

MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

CEO & Director notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

MannKind Corporation Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living with Type 1 Diabetes

MannKind Corporation to Report Q3, 2023 Results on Nov 07, 2023

Price target increased by 9.8% to US$7.25

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

MannKind Corporation to Report Q2, 2023 Results on Aug 07, 2023

Mannkind Corporation Launches Inhale-3 Study to Address the Most Important Unmet Need in Adults Living with Type 1 Diabetes (T1d)

CEO & Director notifies of intention to sell stock

Dr. Burkhard Blank Joins MannKind Corporation as Executive Vice President of Research & Development and Chief Medical Officer

Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 8.1% to US$6.67

Full year 2022 earnings: EPS misses analyst expectations

MannKind Corporation to Report Q4, 2022 Results on Feb 23, 2023

MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

MannKind Corporation Announces its Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Mannkind Corporation Announces Resignation of Alejandro Galindo as Executive Vice President – Endocrine Business Unit, Effective October 21, 2022

MannKind Corporation Successfully Completes Phase 1 Study of Inhaled Clofazimine

Mannkind Corporation: Ready For Your Biotech Portfolio

New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed

MannKind Corporation to Report Q2, 2022 Results on Aug 09, 2022

MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™

Price target decreased to US$5.50

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

Consensus estimates of losses per share improve by 15%

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

High number of new directors

MannKind Corporation, Annual General Meeting, May 10, 2022

Consensus revenue estimates fall by 12%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

MannKind Corporation Provides Update on Tyvaso DPI New Drug Application

MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?

MannKind Corporation to Report Q4, 2021 Results on Feb 24, 2022

MannKind: A Promising Player In The Inhalable Insulin Market

Forecast to breakeven in 2024

Price target increased to US$6.25

Third quarter 2021 earnings released: US$0.018 loss per share (vs US$0.049 loss in 3Q 2020)

Price target decreased to US$5.80